layer1-background

News

 
News
  Date Title View
Apr 12, 2017
Supports potential for OCR-002 in the treatment of NAFLD/NASH Data to be presented at The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 12, 2017 ...
Mar 27, 2017
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 27, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Michael Byrnes, Chief Financial Officer, will be presenting at the upcoming 16th Annual N...
Mar 10, 2017
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 10, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced updates to its clinical development programs and reported financial results for the quarter and year ende...
Mar 8, 2017
IV OCR-002 statistically significantly normalized ammonia faster than standard of care Ammonia reduction statistically significantly correlated with clinical improvement in HE symptoms Ocera plans to meet with FDA in Q3 2017 to inform development paths forward f...
Feb 28, 2017
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming Cowen and Company 37...
Jan 30, 2017
Primary and Secondary Endpoints Showed Trend and Dose-Related Clinical Benefit Although Not Statistically Significant Ammonia Scavenger OCR-002 Demonstrated Statistically Significant Reduction in Ammonia Levels OCR...
Jan 5, 2017
Data Support Feasibility of Oral OCR-002 as Maintenance Therapy for Patients with Hepatic Encephalopathy Company Plans to Initiate Phase 2a in H1 2017 with New Optimized Tablet Formulation PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Oce...
Dec 7, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced it has completed enrollment in its Phase 2b STOP-HE Study evaluating the efficacy, safety and tolerability of Ornithine Phenylacetate (OCR-002) in hos...
Nov 9, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming Stifel 2016 Healthcare...
Nov 2, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today reported financial results for the quarter ended September 30, 2016, and provided updates on its clinical developmen...
1
...
NextLast
= add release to Briefcase